# US 2024/0252531 A1 · Method for decreasing colorectal cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252531 A1
- Document ID: US20240252531A1
- Status: Published application
- Kind: A1
- Application number: 18/599,582
- Filed: 2024-03-08
- Published: 2024-08-01
- Earliest claimed: 2022-01-19
- Assignees: Imam Abdulrahman Bin Faisal University
- Applicants: Imam Abdulrahman Bin Faisal University
- Inventors: Muhammad NAWAZ; Firdos Alam KHAN
- Web page: https://patentgrep.com/patent/US20240252531A1

## CPC

- A61K 33/38: Silver; Compounds thereof
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 33/34: Copper; Compounds thereof
- A61P 35/00: Antineoplastic agents
- C01B 25/45: containing plural metal, or metal and ammonium
- C01G 3/02: Oxides; Hydroxides
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C01P 2002/72: by d-values or two theta-values, e.g. as X-ray diagram
- C01P 2002/82: by IR- or Raman-data
- C01P 2002/84: by UV- or VIS- data
- C01P 2002/85: by XPS, EDX or EDAX data
- C01P 2004/03: obtained by SEM
- C01P 2004/32: Spheres
- C01P 2006/12: Surface area
- C01P 2006/14: Pore volume
- C01P 2006/16: Pore diameter
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C01G: COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts or peroxyacids C01B15/00; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium, or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds containing nitrogen, other non-metals and metal C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS

## Abstract

A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of decreasing an amount of, colorectal cancer cells in a cell culture, comprising:
contacting a composition with the colorectal cancer cells and incubating in a CO2 incubator
wherein the composition comprises Cu—Ag3PO4 substantially spherical nanoparticles having a mean particle size of 100-1,000 nm,
wherein an amount of the Cu—Ag3PO4 nanoparticles is 5.0 to 95 μg per mL of the cell culture,
wherein the Cu—Ag3PO4 nanoparticles have an IC50 of 36-46 μg per mL of the cell culture,
wherein the colorectal cancer cells are HCT-116 cells,
wherein copper is present in the Cu—Ag3PO4 nanoparticles in an amount of 10-15 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4 nanoparticles.

### Claim at position 3

12-20. (canceled)

### Claim 21 (depends on 11)

The method of claim 11, wherein the contacting is for 48 hours.

### Claim 22 (depends on 21)

The method of claim 21, wherein the colorectal cancer cells are incubated in the CO2 incubator for 4 hours.

### Claim 23 (depends on 11)

The method of claim 11, further comprising:
centrifuging the reaction mixture after the precipitating to separate the Cu—Ag3PO4 nanoparticles from the mixture;
washing the Cu—Ag3PO4 nanoparticles with ethanol and water; and
drying the washed Cu—Ag3PO4 nanoparticles at a temperature less than 150° C.

### Claim 24 (depends on 11)

The method of claim 11, wherein the Cu—Ag3PO4 nanoparticles have a BET mean surface area of 4.2-6.1 m2/g.

### Claim 25 (depends on 24)

The method of claim 24, wherein the Cu—Ag3PO4 nanoparticles have a BET mean pore size of 19.5-29.6 nm.

### Claim 26 (depends on 11)

The method of claim 11, wherein during the contacting the Cu—Ag3PO4 nanoparticles are aggregated.

### Claim 27 (depends on 11)

The method of claim 11, wherein the composition consists of the Cu—Ag3PO4 nanoparticles.

### Claim 28 (depends on 11)

The method of claim 11, wherein the Cu—Ag3PO4 nanoparticles have a mean particle size of 200-300 nm.

### Claim 29 (depends on 11)

The method of claim 11, wherein the contacting is in vitro.
